



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Non-Utility Patent Application of

ASHTON et al.

Atty. Ref.: 620-401

Serial No. 10/556,901

Group: unknown

Filed: November 15, 2005

Examiner: Unknown

For: GLYOXALASE INHIBITORS

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

December 16, 2005

Sir:

INFORMATION DISCLOSURE STATEMENT

1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits] N/C
- 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)] N/C
- 2 .(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)] \$180.00
3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

The following are submitted in the above-identified application in compliance with
37 C.F.R. §§ 1.97 and 1.98:

4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.

This paper is submitted in accordance with:

5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- a) The required Statement made in item 8 below; or
- b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
- a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
- b) The required Statement is stated in item 8 below.
8. Statement under 37 CFR 1.97(e)
- a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: _____


B.J. Sadoff
Reg. No. 36,663

901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100


**INFORMATION DISCLOSURE
CITATION**

 ATTY. DOCKET NO. 620-401
 SERIAL NO. 10/556,901
 APPLICANT

ASHTON et al.

(Use several sheets if necessary)

FILING DATE

November 15, 2005

GROUP

unknown

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|-------------------|-----------------|---------|----------------|-------|----------|----------------------------|
| /N.C./ | 4,898,870 | 02/1990 | Narutomi et al | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| DOCUMENT | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION YES | NO |
|--------------------|---------|---------|-------|----------|-----------------|----|
| /N.C./ WO 99/35128 | 07/1999 | WIPO | | | | |
| / J | | | | | | |

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

| | |
|--------|---|
| /N.C./ | Beilstein BRN: 5300594, 5139287, 5137246 & Shestopalov et al, J. Org. Chem. USSR, 1984, 1818-1827 |
| / | Beilstein BRN: 5133758 & Rodinovskaya et al, J. Org. Chem. USSR, Vol. 21, No. 11, 1985, 2230-2235 |
| / | Beilstein BRN: 4489731 & Rodinovskaya et al, Chem. Heterocycl. Compounds (Engl. Transl.), 1988, 658-664 |
| / | Beilstein BRN: 2047546 & Hudgins et al, Biochem. Pharmacol., Vol. 52, No. 8, 1996, 1227-1233 |
| ✓ | Beilstein BRN: 7543266 & Gribble et al, J. Med. Chem., Vol. 39, No. 18, 1996, 3569-3584 |
| / | Beilstein BRN: 1994106, 246624 & Child et al, Arzneim Forsch, Vol. 30, No. 4a, 1980, 695-702 |
| / | Beilstein BRN: 3593422 & Chenard et al, J. Med. Chem., Vol. 33, No. 3, 1990, 1077-1083 |
| / | Beilstein BRN: 2334448 & Lohse et al, J. Agric. Food Chem., Vol. 48, No. 12, 2000, 5913-5923 |
| ✓ | Thornalley et al, Crit. Rev. Oncol. Hematol., Vol. 20, 1995, 99-128 |
| ✓ | Sakamoto et al, Clin. Cancer Res., Vol. 7, 2001, 2513-2518 |
| | Davidson et al, The Journal of Urology, Vol. 161, 1999, 690-691 |
| | Samadi et al, Urology, Vol 57, 2001, 183-187 |
| | Ranganathan et al, Biochimica et Biophysica Acta, Vol 1182, 1993, 311-316 |
| | Sakamoto et al, Blood, Vol. 95, 2000, 3214-3218 |
| | Rulli et al, Breast Canc. Res. Treat, Vol 66, 2001, 67-72 |
| | Thornalley et al, Gen. Pharmacol., Vol 27, No. 4, 1996, 565-573 |
| | Johansson et al, Mol. Pharmacol., Vol. 57, 2000, 619-624 |
| | Thornalley et al, J. Med. Chem., Vol. 39, 1996, 3409-3411 |
| ✓ | Kalsi et al, J. Med. Chem., vol. 43, No. 21, 2000, 3981-3986 |
| /N.C./ | Sharkey et al, Cancer Chemother. Pharmacol., Vol. 46, 2000, 156-166 |

*Examiner /Nilai Chandrakumar/ Date Considered 01/15/2009

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)



**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

620-401

APPUGANTI

SERIAL NO.

10/556,901

(Use several sheets if necessary)

ASHTON et al.

FILED DATE

GROUP

November 15, 2005

unknown

U.S. PATENT DOCUMENTS

**'EXAMINER
INITIAL** **DOCUMENT NUMBER** **DATE** **NAME** **CLASS** **SUBCLASS** **FILING DATE
IF APPROPRIATE**

FOREIGN PATENT DOCUMENTS

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

Thornalley et al, Biochem. Pharmacol., Vol. 51, 1996, 1365-1372
Berge et al, J. Pharm. Sci., Vol. 66, No. 1, 1977, 1-19
Manna et al, Biorg. & Med. Chem. Lett., Vol. 10, 2000, 1883-1885
Salman, Pharmazie, Vol. 54, 1999, 178-183
Racker, J. Biol. Chem., vol. 190, 1951, 685-696
Principato et al, Biochem. International, Vol. 6, No. 2, 1983, 249-255
Ridderstrom et al, Biochem. J., Vol. 314, 1996, 463-467

Examiner

/Nizal Chandrakumar/

Date Considered

01/15/2009

Examiner: Initial if reference considered; whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)